Summary
Based upon the hypothesis that dipyridamole would potentiate the cytotoxicity of mitoxantrone and the combination of 5-fluorouracil (5-FU) and leukovorin, we performed a phase I/II trial of the combination of dipyridamole, 5-FU, leukovorin, and mitoxantrone in patients with metastatic breast cancer. The dose of dipyridamole was fixed at 175 mg/m2 by mouth every 6 h (700 mg/m2/day), based upon a previous phase I trial of oral dipyridamole with 5-FU and leukovorin. Dipyridamole therapy began 24 h prior to the first dose of chemotherapy and continued until 24 h after the last dose of chemotherapy for each course of treatment. At the initial dose level, leukovorin 200 mg/m2 was given intravenously immediately prior to 5-FU 375 mg/ m2 intravenously on days 1–5. Mitoxantrone 6 mg/m2 was given as a single dose on day 3. Unacceptable toxicity was observed at this dose level, leading to successive dose decrements rather than dose increments. The maximum tolerated dose was leukovorin 200 mg/m2 days 1–2, 5-FU 375 mg/m2 days 1–2, mitoxantrone 6 mg/m2 on day 2, and dipyridamole 175 mg/m2 every 6 h on days 0–3. Two responses were produced in 15 patients. This regimen is not recommended for further investigation in the treatment of breast cancer.
Similar content being viewed by others
References
Ehrlichman C, Fine S, Wong A, Elhakim T: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469–475, 1988
Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK, Wiesenfeld: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal cancer. J Clin Oncol 7:1407–1418, 1989
Petrelli N, Douglass HO, Herrera L, Russell D, Stahlein DM, Bruckner HW, Mayer RJ, Schinella R, Green MD, Muggia FM, Megibow A, Greenwald ES, Bukowski RM, Harris J, Levin B, Gaynor E, Loufti A, Kalser MH, Barkin JS, Benedetto P, Woolley PV, Nauta R, Weaver DW, Leichman LP: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7:1419–1426, 1989
Doroshow JH, Leong L, Margolin K, Flanagan B, Goldberg D, Bertrand M, Akman S, Carr B, Odujinrin O, Newman E, Litchfield T: Refractory metastatic breast cancer: salvage therapy with fluorouracil and high dose continuous infusion leucovorin calcium. J Clin Oncol 7:439–444, 1989
Grem JL, Fischer PH: Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole. Cancer Res 45:2967–2972, 1985
Alberts DS, Einspahr, Peng YM, Spearts P: Dipyridamole potentiation of FUDR antitumor activity. Clin Pharm Ther 41:274, 1987
Nelson JA, Drakes S: Potentiation of methotrexate toxicity by dipyridamole. Cancer Res 44:2493–2496, 1984
Howell SB, Hom D, Sanga R, Vick JS, Abramson IS: Comparison of the synergistic potentiation of etoposide, doxorubicin and vinblastine cytoxicity by dipyridamole. Cancer Res 49:3178–3183, 1989
Howell SB, Hom DK, Sanga R, Vick JS, Chan TC: Dipyridamole enhancement of etoposide sensitivity. Cancer Res 49:4147–4153, 1989
Desai PB, Sridahar R: Potentiation of cytoxicity of mitoxantrone toward CHO-K1 cellsin vitro by dipyridamole. Pharm Res 9:178–181, 1992
Budd GT, Jayaraj A, Grabowski D, Adelstein D, Bauer L, Boyett J, Bukowski R, Murthy S, Weick J: Phase I trial of dipyridamole with 5-FU and folinic acid. Cancer Res 50:7206–7211, 1990
Jones SE, Mennel RG, Brooks B, Westrick MA, Allison MA, Paulson RS, Tilmann K, Rea B: Phase II study of metoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer. J Clin Oncol 9:1736–1739, 1991
Hainsworth JD, Andrews MB, Johnson DH, Greco FA: Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well tolerated regimen. J Clin Oncol 9:1731–1735, 1991
Swain SM, Honig SF: Mitoxantrone, 5-FU, and leukovorin in breast cancer. Med Pediatr Oncol 22:370–374, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Budd, G.T., Herzog, P. & Bukowski, R.M. Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer. Invest New Drugs 12, 283–287 (1994). https://doi.org/10.1007/BF00873042
Issue Date:
DOI: https://doi.org/10.1007/BF00873042